|
Parameters
|
Total (n = 342)
|
Tertile 1 (n = 114)
|
Tertile 2 (n = 114)
|
Tertile 3 (n = 114)
|
P value
|
|---|
|
Home monitoring data
|
|
Baseline PA, %
|
10.80 ± 5.35
|
5.18 ± 2.01
|
10.30 ± 1.48
|
16.93 ± 3.19
|
–
|
|
Baseline HRV, ms
|
71.14 ± 27.63
|
62.40 ± 25.43
|
72.23 ± 26.87
|
78.80 ± 28.85
|
–
|
|
Demographics
|
|
Gender, male
|
78.4% (268)
|
76.3% (87)
|
74.6% (85)
|
84.2% (96)
|
P = 0.169
|
|
Age at implantation, years
|
62.37 ± 13.48
|
66.32 ± 13.66
|
63.26 ± 13.07
|
57.52 ± 12.26
|
P < 0.001
|
|
BMI, Kg/m2
|
23.56 ± 2.87
|
23.62 ± 2.85
|
23.53 ± 3.26
|
23.72 ± 2.45
|
P = 0.890
|
|
CRT-D implantation
|
53.8% (184)
|
51.8% (59)
|
57.9% (66)
|
51.8% (59)
|
P = 0.562
|
|
NYHA, Class III-IV
|
61.4% (210)
|
67.5% (77)
|
61.4% (70)
|
55.3% (63)
|
P = 0.163
|
|
Echocardiography
|
|
LVEF, %
|
39.13 ± 14.43
|
38.64 ± 14.61
|
39.48 ± 14.20
|
39.29 ± 14.60
|
P = 0.900
|
|
LVEDD, mm
|
62.38 ± 13.20
|
60.17 ± 11.36
|
62.76 ± 13.69
|
64.23 ± 14.18
|
P = 0.066
|
|
Comorbidities
|
|
Hypertension
|
35.1% (120)
|
39.5% (45)
|
43.0% (49)
|
22.8% (26)
|
P = 0.003
|
|
DM
|
14.6% (50)
|
17.5% (20)
|
14.0% (16)
|
12.3% (14)
|
P = 0.519
|
|
Stroke
|
2.6% (9)
|
7.0% (8)
|
0.9% (1)
|
0.0% (0)
|
P = 0.001
|
|
DCM
|
29.8% (102)
|
28.9% (33)
|
29.8% (34)
|
30.7% (35)
|
P = 0.959
|
|
HCM
|
3.8% (13)
|
0.9% (1)
|
5.3% (6)
|
5.3% (6)
|
P = 0.081
|
|
ICM
|
39.8% (136)
|
47.7% (54)
|
42.1% (48)
|
29.8% (34)
|
P = 0.021
|
|
Valve disease
|
2.3% (8)
|
3.5% (4)
|
1.8% (2)
|
1.8% (2)
|
P = 0.671
|
|
Prior MI
|
14.0% (48)
|
20.2% (23)
|
12.3% (14)
|
9.6% (11)
|
P = 0.059
|
|
PCI
|
11.7% (40)
|
21.1% (24)
|
9.6% (11)
|
4.4% (5)
|
P < 0.001
|
|
CABG
|
1.8% (6)
|
3.5% (4)
|
0.0% (0)
|
1.8% (2)
|
P = 0.060
|
|
Prior paroxysmal AF
|
7.6% (26)
|
9.6% (11)
|
7.0% (8)
|
6.1% (7)
|
P = 0.582
|
|
LQTS
|
1.5% (5)
|
0.9% (1)
|
1.8% (2)
|
1.8% (2)
|
P = 0.801
|
|
Pre-implant syncope
|
15.8% (54)
|
19.3% (22)
|
9.6% (11)
|
18.4% (21)
|
P = 0.087
|
|
Medication
|
|
ACEIs/ARBs
|
41.5% (142)
|
43.0% (49)
|
43.9% (50)
|
37.7% (43)
|
P = 0.596
|
|
Diuretics
|
33.0% (113)
|
39.5% (45)
|
31.6% (36)
|
28.1% (32)
|
P = 0.172
|
|
Aldosterone antagonists
|
45.0% (154)
|
51.8% (59)
|
41.2% (47)
|
42.1% (48)
|
P = 0.208
|
|
CCBs
|
10.2% (35)
|
2.0% (7)
|
5.6% (19)
|
2.6% (9)
|
P = 0.019
|
|
Statins
|
22.8% (78)
|
24.6% (28)
|
28.1% (32)
|
15.8% (18)
|
P = 0.075
|
|
Beta-blockers
|
57.6% (197)
|
57.0% (65)
|
57.9% (66)
|
57.9% (66)
|
P = 0.988
|
|
Amiodarone
|
28.1% (96)
|
27.2% (31)
|
23.7% (27)
|
33.3% (38)
|
P = 0.260
|
|
Antiplatelets
|
21.6% (74)
|
27.2% (31)
|
22.8% (26)
|
14.9% (17)
|
P = 0.074
|
- ACEIs angiotensin-converting enzyme inhibitors, AF atrial fibrillation, ARBs angiotensin receptor blockers, BMI body mass index, CABG coronary artery bypass grafting, CCB calcium channel blockers, CRT-D cardiac resynchronization therapy with defibrillation, DCM dilated cardiomyopathy, DM diabetes mellitus, HCM hypertrophic cardiomyopathy, HRV heart rate variability, ICM ischemic cardiomyopathy, LQTS long QT syndrome, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, MI myocardial infarction, PA physical activity, PCI percutaneous coronary intervention
